Results of medical and social research and assessment of quality of life in myasthenia gravis
Authors:
- Yu. A. MerkulovYMYu. A. Merkulov
- V. M. AlifirovaVAV. M. Alifirova
- M. V. AmbroskinaMAM. V. Ambroskina
- K. Z. BakhtiyarovaKBK. Z. Bakhtiyarova
- S. B. BlinovaSBS. B. Blinova
- Z. A. GoncharovaZGZ. A. Goncharova
- N. Yu. GorokhovaNGN. Yu. Gorokhova
- I. V. GreshnovaIGI. V. Greshnova
- L. G. ZaslavskyLZL. G. Zaslavsky
- E. V. KrivomlinaEKE. V. Krivomlina
- E. A. LunevaELE. A. Luneva
Open Access
- 20 October 2025
- journal article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (5) , 11-20
Abstract
Myasthenia gravis (MG) is one of the most common autoimmune diseases of the nervous system. Medical and social analysis of the patient population structure and assessment of their quality of life (QoL) as one of the criteria for the effectiveness of treatment are of great importance for evaluating the condition of patients and the directions of development of specialised care.Objective: to analyse the quality of life of patients diagnosed with MG.Material and methods. The study involved 662 patients with MG from 26 regions of Russia. A specially designed medical and social questionnaire and the SF-36 questionnaire were used.Results. In Russia, women and middle-aged and elderly people predominate among MG patients. MG is characterised by a relatively favourable course (less than half of patients have any form of disability). Almost two-thirds of patients have other chronic diseases. About 90% of MG patients receive drug therapy, but almost half of patients have problems obtaining their prescribed medication. In addition to a significant decrease in physical activity, there is also a decrease in the mental state of patients associated with various physical disorders, as well as fear of the future (fear of symptom recurrence, risk of being left without support and unable to perform daily tasks, the need for lifelong treatment). Among the symptoms of MG that affect the emotional state of patients, weakness and rapid fatigue are in first place, followed by bulbar dysfunction. The role functioning of patients with MG depends to a greater extent on their physical condition and to a lesser extent on their emotional state. Those receiving regular drug therapy had significantly better indicators than those who were not treated. The SF-36 scale assessment confirmed that physical condition and physical functioning, which influence the psychological components of QoL assessment, are crucial for QoL in MG.Conclusion. A significant decrease in QoL indicators was noted in MG, primarily in the physical component and, secondarily, in psychological health. All this points to the need for early initiation of highly effective pathogenetic therapy, in particular with modern C5-complement inhibitors.Keywords
This publication has 20 references indexed in Scilit:
- Assessing the effectiveness of measurement scales in evaluating the health-related quality of life in rare disease patients after treatment: a systematic reviewHealth and Quality of Life Outcomes, 2024
- Targeted Treatments for Myasthenia Gravis in Children and AdolescentsPediatric Drugs, 2024
- Myasthenia gravis. Update on diagnosis and therapyMedicina Clínica (English Edition), 2023
- Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MGBMJ Open, 2023
- Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia GravisJournal of Comparative Effectiveness Research, 2022
- Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care dataPLOS ONE, 2021
- Impact of Refractory Myasthenia Gravis on Health-Related Quality of LifeJournal of Clinical Neuromuscular Disease, 2019
- Long‐term safety and efficacy of eculizumab in generalized myasthenia gravisMuscle & Nerve, 2019
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyThe Lancet Neurology, 2017
- An up-date on health-related quality of life in myasthenia gravis -results from population based cohortsHealth and Quality of Life Outcomes, 2015